Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Avalo Therapeutics, Inc. - Common Stock (NQ:AVTX)

18.85 +0.37 (+2.00%)

Streaming Delayed Price Updated: 10:04 AM EDT, Jul 1, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	87,132
Open	18.43
Bid (Size)	18.75 (200)
Ask (Size)	18.85 (100)
Prev. Close	18.48
Today's Range	18.35 - 18.99
52wk Range	4.610 - 24.27
Shares Outstanding	96,008,951
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes

June 26, 2026

From Avalo Therapeutics

Via GlobeNewswire

Avalo Therapeutics Appoints Ron Philip to Board of Directors

June 23, 2026

From Avalo Therapeutics

Via GlobeNewswire

Performance

YTD	+10.8%	+10.8%
1 Month	+19.7%	+19.7%
3 Month	+26.3%	+26.3%
6 Month	+5.8%	+5.8%
1 Year	+277.8%	+277.8%

More News

Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody

June 16, 2026

From Avalo Therapeutics

Via GlobeNewswire

Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

May 22, 2026

From Avalo Therapeutics

Via GlobeNewswire

Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

May 13, 2026

From Avalo Therapeutics

Via GlobeNewswire

Avalo Therapeutics Stock Soars After Positive LOTUS Trial Results ↗

May 06, 2026

Via Benzinga

Wednesday's session: gap up and gap down stocks ↗

May 06, 2026

Via Chartmill

These stocks are moving in today's pre-market session ↗

May 06, 2026

Via Chartmill

Avalo Therapeutics Announces Pricing of $375 Million Public Offering

May 05, 2026

From Avalo Therapeutics

Via GlobeNewswire

Get insights into the top gainers and losers of Tuesday's after-hours session. ↗

May 05, 2026

Via Chartmill

Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

May 05, 2026

From Avalo Therapeutics

Via GlobeNewswire

Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa

May 05, 2026

From Avalo Therapeutics

Via GlobeNewswire

Avalo Therapeutics Purchases Optional Milestone Buyout

April 28, 2026

From Avalo Therapeutics

Via GlobeNewswire

Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates

March 23, 2026

From Avalo Therapeutics

Via GlobeNewswire

Avalo Therapeutics to Participate in Upcoming Investor Conferences

February 24, 2026

From Avalo Therapeutics

Via GlobeNewswire

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

February 18, 2026

From Avalo Therapeutics

Via GlobeNewswire

Avalo Therapeutics to Participate in Upcoming Investor Conferences

February 04, 2026

From Avalo Therapeutics

Via GlobeNewswire

Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

November 06, 2025

From Avalo Therapeutics

Via GlobeNewswire

Avalo Therapeutics to Participate in Upcoming Investor Conferences

November 03, 2025

From Avalo Therapeutics

Via GlobeNewswire

Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

October 29, 2025

From Avalo Therapeutics

Via GlobeNewswire

Avalo Therapeutics Stock Rises Premarket Ahead Of Oppenheimer Call On Lead Hidradenitis Drug ↗

October 22, 2025

Via Stocktwits

Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

October 01, 2025

From Avalo Therapeutics

Via GlobeNewswire

Wondering what's happening in today's pre-market session? ↗

September 29, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 29, 2025

Via Benzinga

Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket ↗

September 29, 2025

Via Benzinga

Frequently Asked Questions

Is Avalo Therapeutics, Inc. - Common Stock publicly traded?

Yes, Avalo Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Avalo Therapeutics, Inc. - Common Stock trade on?

Avalo Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Avalo Therapeutics, Inc. - Common Stock?

The ticker symbol for Avalo Therapeutics, Inc. - Common Stock is AVTX on the Nasdaq Stock Market

What is the current price of Avalo Therapeutics, Inc. - Common Stock?

The current price of Avalo Therapeutics, Inc. - Common Stock is 18.85

When was Avalo Therapeutics, Inc. - Common Stock last traded?

The last trade of Avalo Therapeutics, Inc. - Common Stock was at 07/01/26 10:04 AM ET

What is the market capitalization of Avalo Therapeutics, Inc. - Common Stock?

The market capitalization of Avalo Therapeutics, Inc. - Common Stock is 1.81B

How many shares of Avalo Therapeutics, Inc. - Common Stock are outstanding?

Avalo Therapeutics, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.